Kent Lake Nominates Three Highly Qualified, Independent Candidates for Quanterix Board
Kent Lake PR LLC (“Kent Lake”), a holder of 6.9% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (
NASDAQQTRX), announced today it has nominated three highly qualified, independent candidates for election to the Company’s Board of Directors (the “Board”) at the 2025 Annual Meeting of Shareholders (the “Annual Meeting”).
Quanterix Highlights Compelling Benefits of Akoya Biosciences Acquisition
Quanterix Corporation (
NASDAQQTRX) (“Quanterix” or the “Company”), a company fueling scientific discovery through ultra-sensitive biomarker detection, today reiterated the strategic and financial benefits of its proposed acquisition of Akoya Biosciences, which will create the first integrated solution for ultra-sensitive detection of blood- and tissue-based protein biomarkers. Quanterix issued the following statement:
Kent Lake Issues Letter to Quanterix Shareholders Regarding Opposition to the Company’s Proposed Merger with Akoya Biosciences
Kent Lake PR LLC (“Kent Lake”), a holder of 5.9% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (
NASDAQQTRX), today highlighted its opposition to the Company’s proposed merger (the “Merger”) with Akoya Biosciences (“Akoya”)
NASDAQ: AKYANASDAQAKYA)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IVAC, AVTE, QTRX on Behalf of ShareholdersNEW YORK, Feb. 17, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Bragar Eagel & Squire, P.C. Is Investigating Quanterix and TransMedics and Encourages Investors to Contact the FirmNEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Quanterix Corporation (
NASDAQQTRX) and TransMedics Group, Inc.
NASDAQ:TMDXNASDAQTMDX)
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates LGTY, AZPN, RDW, QTRX on Behalf of ShareholdersNEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CCRN, NARI, VTS, QTRX on Behalf of ShareholdersNEW YORK, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NARI, QTRX, CTV on Behalf of ShareholdersNEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Quanterix Provides Update on Financial Performance
Quanterix Corporation (
NASDAQQTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced selected preliminary, unaudited results for the fourth quarter and full year ended December 31, 2024.
QTRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Quanterix Corporation Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Quanterix Corporation (
NASDAQQTRX) and Akoya Biosciences, Inc. is fair to Quanterix shareholders. Upon completion of the proposed transaction, Quanterix shareholders will own approximately 70% of the combined company.
David R. Walt Receives National Medal of Technology and Innovation
Quanterix Corporation (
NASDAQQTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that David R. Walt, co-inventor of the Company’s Simoa technology has received the National Medal of Technology and Innovation, bestowed by the President of the United States.
Quanterix to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Quanterix Corporation (
NASDAQQTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Executive Officer Masoud Toloue will present at the 43rd Annual J.P. Morgan Healthcare Conference taking place January 13th-16th at the Westin St. Francis Hotel in San Francisco, CA. Quanterix’s presentation will be on Wednesday, January 15, 2025, at 4:30 p.m., PST. In addition to the session, Quanterix will also host one-on-one meetings with institutional investors during the conference.
Quanterix Expands Capabilities with Strategic Acquisition of EMISSION
Quanterix Corporation (
NASDAQQTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced the acquisition of EMISSION iNC. (“EMISSION”). Quanterix expects the transaction will close in January 2025.
